Bavaria is at the forefront of life science development—both in Germany and across Europe. No other state has defined and implemented such ambitious policies. The Bavarian state government has invested EUR 500 million in biotechnology infrastructure, science and incubators over the last few decades.
These funds have been complemented by private sector investments in Bavarian biotech companies of well over EUR 3.5 billion leading to success. Bavarian biotech has increased from 30 companies in 1995 to more than 200 currently. From some 2,500 employees in 1995, the biotech branch has increased to nearly 12,000 employees today. And from zero drugs being marketed by biotech SME in 1995, today there are 7 drugs on the market derived from Bavarian biotech SME. Together with pharma, CROs, CMOs and suppliers, the Bavarian biopharmaceutical industry employs 30,000 people.
Bavaria is committed to continuing to support and accelerate biomedical innovation to serve the global patient´s community.
To hear about opportunities for partnerships in Bavaria, there will be a press conference hosted by BioM Biotech Cluster Development GmbH at BIO-Europe® 2015 in Munich on November 2 entitled “Bavaria: Innovation by Tradition.”
- Date: Monday, November 11, 2015, 9:45–10:30 am
- Place: BIO-Europe 2015 Bavarian Booth, Hall B1, Booth 74
- Moderator: Professor Horst Domdey
- Participants: Bavaria´s State Deputy Josef Pschierer; Dr. Simon Moroney (CEO MorphoSys); and Dr. Christine Guenther (CEO apceth)
- Topics: 20 years from scratch: Facts and figures from the Bavarian Biotechnology industry, new announcements, and recent global innovation in Bavaria
Click here for information on BIO-Europe 2015.